These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34459148)

  • 21. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
    Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel pyrazolo[3,4-d]pyrimidine derivatives inhibit human cancer cell proliferation and induce apoptosis by ROS generation.
    Gaonkar S; Savanur MA; Nadaf AA; Najare MS; Mantur S; Garbhagudi M; Mulla SI; Khazi IAM
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900296. PubMed ID: 32073686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
    Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel pyrazolo[3,4-d]pyrimidine derivatives as potential antitumor agents: exploratory synthesis, preliminary structure-activity relationships, and in vitro biological evaluation.
    He HY; Zhao JN; Jia R; Zhao YL; Yang SY; Yu LT; Yang L
    Molecules; 2011 Dec; 16(12):10685-94. PubMed ID: 22186955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
    Somakala K; Tariq S; Amir M
    Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors.
    Shaaban MA; Elshaier YAMM; Hammad AH; Farag NA; Hassan Haredy H; AbdEl-Ghany AA; Mohamed KO
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127337. PubMed ID: 32631538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.
    Venkatesan G; Paira P; Cheong SL; Federico S; Klotz KN; Spalluto G; Pastorin G
    Eur J Med Chem; 2015 Mar; 92():784-98. PubMed ID: 25633494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inflammatory drug approach: Synthesis and biological evaluation of novel pyrazolo[3,4-d]pyrimidine compounds.
    Atatreh N; Youssef AM; Ghattas MA; Al Sorkhy M; Alrawashdeh S; Al-Harbi KB; El-Ashmawy IM; Almundarij TI; Abdelghani AA; Abd-El-Aziz AS
    Bioorg Chem; 2019 May; 86():393-400. PubMed ID: 30763886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
    Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
    Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of pyrazolo[1,5-a]pyrimidine derivatives and their antifungal activities against phytopathogenic fungi in vitro.
    Zhang J; Peng JF; Bai YB; Wang P; Wang T; Gao JM; Zhang ZT
    Mol Divers; 2016 Nov; 20(4):887-896. PubMed ID: 27599494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.
    Zhang S; Ulrich M; Gromnicka A; Havlíček L; Kryštof V; Jorda R; Strnad M; Vollmar AM; Zahler S
    Br J Pharmacol; 2016 Sep; 173(17):2645-56. PubMed ID: 27390037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.
    Wustrow DJ; Capiris T; Rubin R; Knobelsdorf JA; Akunne H; Davis MD; MacKenzie R; Pugsley TA; Zoski KT; Heffner TG; Wise LD
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2067-70. PubMed ID: 9873487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors.
    Hauck S; Hiesinger K; Khageh Hosseini S; Achenbach J; Biondi RM; Proschak E; Zörnig M; Odadzic D
    Bioorg Med Chem; 2016 Nov; 24(22):5717-5729. PubMed ID: 27729195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.